Latest Ratios: P/E Ratio -2.6x · EV/EBITDA 9.5x · ROE -41.4%. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.9B | $1.3B | $3.7B | $7.1B | $7.5B | $5.5B | $4.5B | $2.9B | $2.2B | $2.8B | $2.8B |
| Enterprise Value | $5.5B | $3.8B | $5.7B | $8.5B | $9.0B | $7.0B | $7.3B | $6.1B | $5.4B | $6.0B | $6.1B |
| P/E Ratio → | -2.63 | — | 14.26 | — | 27.62 | 28.90 | — | 26.79 | — | 14.19 | 472.86 |
| P/S Ratio | 0.89 | 0.39 | 1.16 | 2.41 | 2.89 | 2.38 | 2.13 | 1.45 | 0.74 | 1.00 | 1.01 |
| P/B Ratio | 1.35 | 0.60 | 1.14 | 2.45 | 2.60 | 2.13 | 2.34 | 1.16 | 0.95 | 1.09 | 1.30 |
| P/FCF | — | — | — | 185.10 | 89.28 | 42.50 | 10.07 | 60.50 | 30.90 | 22.65 | 52.69 |
| P/OCF | 22.27 | 9.76 | 28.14 | 15.30 | 19.80 | 14.72 | 6.76 | 8.76 | 5.42 | 7.11 | 7.87 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.15 | 1.79 | 2.90 | 3.44 | 3.03 | 3.51 | 3.02 | 1.79 | 2.12 | 2.16 |
| EV / EBITDA | 9.46 | 6.60 | 8.42 | 13.28 | 15.32 | 13.46 | 16.77 | 8.10 | 9.43 | 10.35 | 10.47 |
| EV / EBIT | 14.07 | — | 12.35 | 149.44 | 20.20 | 19.89 | 21.44 | 19.34 | 21.38 | 13.73 | 13.65 |
| EV / FCF | — | — | — | 222.02 | 106.24 | 54.11 | 16.58 | 125.97 | 74.18 | 47.95 | 112.51 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 17.6% | 17.6% | 22.6% | 23.3% | 96.2% | 96.1% | 95.8% | 40.6% | 41.0% | 41.8% | 41.0% |
| Operating Margin | 11.7% | 11.7% | 16.6% | 17.3% | 17.9% | 17.9% | — | 32.9% | 13.7% | 15.4% | 15.8% |
| Net Profit Margin | -33.3% | -33.3% | 8.1% | -0.7% | 10.5% | 8.2% | -32.2% | 5.4% | -5.8% | 7.0% | 0.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -41.4% | -41.4% | 8.4% | -0.7% | 10.0% | 8.5% | -30.5% | 4.5% | -7.1% | 8.4% | 0.3% |
| ROA | -19.2% | -19.2% | 4.5% | -0.4% | 5.6% | 3.4% | -10.0% | 1.7% | -2.8% | 3.2% | 0.1% |
| ROIC | 5.9% | 5.9% | 8.2% | 8.8% | 8.3% | 7.0% | — | 8.9% | 5.5% | 5.9% | 7.1% |
| ROCE | 7.5% | 7.5% | 10.6% | 11.2% | 10.4% | 8.7% | — | 10.9% | 7.0% | 7.5% | 9.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.24 | 1.24 | 0.65 | 0.52 | 0.53 | 0.63 | 1.71 | 1.30 | 1.35 | 1.25 | 1.50 |
| Debt / EBITDA | 4.60 | 4.60 | 3.10 | 2.36 | 2.61 | 3.14 | 7.45 | 4.35 | 5.59 | 5.58 | 5.67 |
| Net Debt / Equity | — | 1.18 | 0.63 | 0.49 | 0.49 | 0.58 | 1.52 | 1.26 | 1.33 | 1.22 | 1.48 |
| Net Debt / EBITDA | 4.37 | 4.37 | 2.99 | 2.21 | 2.45 | 2.89 | 6.59 | 4.21 | 5.50 | 5.46 | 5.57 |
| Debt / FCF | — | — | — | 36.92 | 16.96 | 11.60 | 6.51 | 65.47 | 43.28 | 25.30 | 59.82 |
| Interest Coverage | -6.68 | -6.68 | 3.94 | 0.69 | 6.36 | 4.58 | 2.16 | 1.68 | 1.36 | 2.49 | 2.45 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.55 | 1.55 | 1.00 | 0.67 | 1.30 | 1.22 | 1.93 | 1.17 | 1.08 | 1.25 | 1.25 |
| Quick Ratio | 1.54 | 1.54 | 0.99 | 0.67 | 1.29 | 1.21 | 1.93 | 1.16 | 1.07 | 1.24 | 1.23 |
| Cash Ratio | 0.25 | 0.25 | 0.13 | 0.11 | 0.25 | 0.33 | 0.29 | 0.21 | 0.12 | 0.18 | 0.17 |
| Asset Turnover | — | 0.60 | 0.53 | 0.55 | 0.52 | 0.49 | 0.32 | 0.29 | 0.49 | 0.44 | 0.47 |
| Inventory Turnover | 480.01 | 480.01 | 431.90 | 423.80 | 19.70 | 18.95 | 17.98 | 292.73 | 351.86 | 344.81 | 358.14 |
| Days Sales Outstanding | — | 60.07 | 48.83 | 53.53 | 49.46 | 48.01 | 51.88 | 58.35 | 38.54 | 44.39 | 40.87 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 7.0% | — | 3.6% | 3.5% | — | 3.7% | — | 7.0% | 0.2% |
| FCF Yield | — | — | — | 0.5% | 1.1% | 2.4% | 9.9% | 1.7% | 3.2% | 4.4% | 1.9% |
| Buyback Yield | 1.7% | 3.9% | 0.2% | 0.0% | 0.0% | 0.1% | 0.0% | 0.1% | 0.2% | 0.1% | 0.0% |
| Total Shareholder Yield | 1.7% | 3.9% | 0.2% | 0.0% | 0.0% | 0.1% | 0.0% | 0.1% | 0.2% | 0.1% | 0.0% |
| Shares Outstanding | — | $91M | $92M | $91M | $92M | $91M | $89M | $88M | $87M | $87M | $86M |
Clinical labor cost inflation
According to recent market data, Acadia's negative trailing P/E of -2.25 and forward P/E of 18.19 suggest that investors are struggling to anchor valuation to current earnings, as the market appears to be pricing in a recovery from non-recurring charges rather than current operational performance.
The wide gap between trailing and forward multiples indicates that the market is discounting the recent massive net losses as transitory. Investors should monitor whether the forward multiple of 18.19 is justified by sustainable margin expansion or if it reflects an overly optimistic view of the company's ability to normalize profitability in a high-wage environment.
Based on reported figures, Acadia's ROIC has languished in the low single digits, peaking at only 2.2% in recent quarters, which suggests that the company is failing to generate returns on invested capital that exceed its likely cost of capital in the current interest rate environment.
The persistent inability to drive ROIC above 2.5% highlights the capital-intensive nature of the facility-based model and the drag caused by underperforming assets. This trend warrants investigation into whether the joint venture strategy is truly accretive or if the high cost of maintaining and staffing these facilities is structurally suppressing long-term compounding potential.
As reported in financial statements, the cash conversion cycle has swung wildly from -627 days to 41 days, indicating that Acadia's ability to manage its working capital is highly inconsistent and likely influenced by the timing of government supplemental payments and large, non-recurring accounts payable adjustments.
The extreme volatility in the CCC suggests that the company lacks a stable operational rhythm in its cash management. Investors should be wary of these fluctuations, as they may mask underlying difficulties in collecting receivables from commercial payers or managing the timing of clinical labor expenditures.
Based on recent filings, Acadia's debt-to-equity ratio has climbed to 1.23 in 2026Q1 from 0.52 in 2023Q4, signaling a shift toward higher financial leverage as the company relies increasingly on debt financing to fund its capital-intensive facility expansion and cover ongoing operational cash outflows.
The rapid increase in leverage, combined with an interest coverage ratio that has dipped as low as -29.83 in 2025Q4, suggests that debt service is becoming increasingly precarious. This trend warrants close monitoring, as any further deterioration in operating income could severely limit the company's financial flexibility and ability to refinance existing obligations.
The P/E ratio is the most commonly misapplied metric for Acadia, as it fails to account for the massive non-cash impairments and legal accruals that frequently distort net income, thereby providing a misleading picture of the company's true cash-generating capacity and operational health.
Analysts should instead prioritize EV/EBITDA or FCF-based metrics to strip away the noise of non-recurring accounting charges. Relying on P/E in this context obscures the reality that the company's earnings are currently decoupled from its actual cash flow, leading to a potentially dangerous misinterpretation of the firm's valuation floor.
Includes 30+ ratios · 15 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ACHC stock.
Acadia Healthcare Company, Inc.'s current P/E ratio is -2.6x. The historical average is 32.0x.
Acadia Healthcare Company, Inc.'s current EV/EBITDA is 9.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 13.5x.
Acadia Healthcare Company, Inc.'s return on equity (ROE) is -41.4%. The historical average is -2.5%.
Based on historical data, Acadia Healthcare Company, Inc. is trading at a P/E of -2.6x. Compare with industry peers and growth rates for a complete picture.
Acadia Healthcare Company, Inc. has 17.6% gross margin and 11.7% operating margin. Operating margin between 10-20% is typical for established companies.
Acadia Healthcare Company, Inc.'s Debt/EBITDA ratio is 4.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.